top
Search terms
Results 1 - 10 of 105 - ordered by :
Pages: 1 2 3 4 5 6 7 ... 11
Date : 07/02/2016 Item size : 176457 bytes
Ehjournal

Alirocumab effect on the rate of diabetes-related treatment-emergent adverse events (TEAEs), and/or fasting plasma glucose (FPG) and glycated haemoglobin A1C (HbA1C) was measured at baseline and ...

European Heart Journal, Clinical Research, Helen M. Colhoun, Henry N. Ginsberg, Jennifer G. Robinson, Lawrence A. Leiter, Dirk Müller-Wieland, Robert R. Henry, Bertrand Cariou, Marie T. ...

Date : 14/10/2016 Item size : 336872 bytes
Ehjournal

The Framingham study and numerous cohorts thereafter subsequently confirmed the prognostic value of cholesterol and in particular LDL-cholesterol, and the 4S Trial2 eventually proved the cholesterol ...

European Heart Journal, Issue @ A Glance, Thomas F. Lüscher

Date : 14/10/2016 Item size : 197432 bytes
Ehjournal

Download the Issue @ a Glance podcast Subscribe to the EHJ Podcast Elevated levels of LDL-cholesterol are determined mainly genetically1 and are the most important risk factor for atherosclerosis in ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 01/05/2016
Ehjournal

Paul M. Ridker Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, 900 Commonwealth Avenue, Boston, MA 02215, USADivisions of Preventive Medicine and Cardiovascular Diseases, ...

European Heart Journal, CLINICAL RESEARCH, Paul M. Ridker, Nader Rifai, Gary Bradwin, Lynda Rose

Date : 07/02/2016
Ehjournal

Abstract Aims To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin 9, ...

European Heart Journal, Coronary artery disease, Christopher P. Cannon, Bertrand Cariou, Dirk Blom, James M. McKenney, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari, Helen M. Colhoun

Date : 14/05/2015
Ehjournal

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study Results Participants Between 27 June ...

European Heart Journal, CLINICAL RESEARCH, John J.P. Kastelein, Steven E. Nissen, Daniel J. Rader, G. Kees Hovingh, Ming-Dauh Wang, Tong Shen, Kathryn A. Krueger

Date : 01/05/2016
Ehjournal

Furthermore, the EMPA-REG OUTCOME trial using the novel antihyperglycaemic agent, empagliflozin,8 a selective sodiumglucose co- transporter inhibitor, significantly reduced cardiovascular mortality; ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 07/02/2016
Ehjournal

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs able to decrease LDL-C by 5070% when administered either as a monotherapy or on a background with statins.46 ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 21/09/2015
Ehjcvp

Differences between sexes and during pubertal development suggest an influence of sex hormones on plasma PCSK9 concentrations There were no sex differences in PCSK9 concentrations in young adults, ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Eliano P. Navarese, Michalina Kołodziejczak, Dimitrios Dimitroulis, Georg Wolff, Hans L. Busch, Fiorella Devito, Alessandro ...

Date : 01/01/2016